Compare Incyte Corporation (INCY) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Twilio Inc — how do they compare? Incyte Corporation trades at $117.62 (market cap $23.11B), while Twilio Inc trades at $201.17 (market cap $31.15B). The key difference: Twilio Inc is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, Twilio Inc nearer its low. Which is the better fit depends on your goals.
| INCY | TWLO | |
|---|---|---|
Market Cap | $23.11B | $31.15B |
Sector | Health | Technology |
52-Week High | $118.52 | $236.64 |
52-Week Low | $67.38 | $92.44 |
Enterprise Value | $19.13B | $29.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Twilio (TWLO) trades at $208.56, up 0.86% with a bullish technical outlook. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 6, 2026. Revenue grew to $5.07B in 2025, and net income turned positive at $33.83M. Analyst sentiment is strongly positive with a consensus price target of $223.00. Operating cash flow improved significantly to $1.00B in 2025, indicating strengthening financial health.
The outlook for Twilio is optimistic due to consistent earnings beats and robust revenue growth, though high valuation multiples pose risks. Key opportunities include AI-driven communication tools and margin expansion under new leadership. Risks include intense competition and execution challenges in sustaining profitability. Investors should monitor Q2 2026 earnings for continued momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
